- Karolinska Development breddar sin portfölj genom nyinvestering i BOOST Pharma
- Karolinska Development invests in BOOST Pharma, expanding its portfolio
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
More ▼
Key statistics
On Friday, Karolinska Development AB (KDEV:STO) closed at 1.50, 6.52% above its 52-week low of 1.41, set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.53 |
---|---|
High | 1.53 |
Low | 1.48 |
Bid | 1.50 |
Offer | 1.50 |
Previous close | 1.53 |
Average volume | 288.82k |
---|---|
Shares outstanding | 267.52m |
Free float | 94.55m |
P/E (TTM) | 12.11 |
Market cap | 403.42m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of Jun 07 2024 17:00 BST.
More ▼